↓ Skip to main content

A novel model-based approach for dose determination of glycopyrronium bromide in COPD

Overview of attention for article published in BMC Pulmonary Medicine, December 2012
Altmetric Badge

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
57 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A novel model-based approach for dose determination of glycopyrronium bromide in COPD
Published in
BMC Pulmonary Medicine, December 2012
DOI 10.1186/1471-2466-12-74
Pubmed ID
Authors

Helen Arievich, Tim Overend, Didier Renard, Michael Gibbs, Vijay Alagappan, Michael Looby, Donald Banerji

Abstract

Glycopyrronium bromide (NVA237) is an inhaled long-acting muscarinic antagonist in development for treatment of COPD. This study compared the efficacy and safety of once-daily (OD) and twice-daily (BID) glycopyrronium bromide regimens, using a novel model-based approach, in patients with moderate-to-severe COPD.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
Australia 1 2%
Brazil 1 2%
Unknown 54 95%

Demographic breakdown

Readers by professional status Count As %
Other 12 21%
Researcher 9 16%
Student > Master 6 11%
Student > Postgraduate 4 7%
Student > Doctoral Student 3 5%
Other 10 18%
Unknown 13 23%
Readers by discipline Count As %
Medicine and Dentistry 23 40%
Pharmacology, Toxicology and Pharmaceutical Science 6 11%
Nursing and Health Professions 3 5%
Agricultural and Biological Sciences 3 5%
Biochemistry, Genetics and Molecular Biology 2 4%
Other 3 5%
Unknown 17 30%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 December 2012.
All research outputs
#16,626,277
of 21,339,655 outputs
Outputs from BMC Pulmonary Medicine
#1,131
of 1,726 outputs
Outputs of similar age
#214,535
of 291,470 outputs
Outputs of similar age from BMC Pulmonary Medicine
#47
of 60 outputs
Altmetric has tracked 21,339,655 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,726 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one is in the 27th percentile – i.e., 27% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 291,470 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 60 others from the same source and published within six weeks on either side of this one. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.